http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 Jan 2026 08:02:08 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html <p>ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company, announced the appointment of Jonathan Rigby to its board of directors.</p> <p>Rigby currently serves as Chief Executive Officer of Sernova Biotherapeutics. He previously held the position of President and Chief Executive Officer at Revolo Biotherapeutics, where he led the company through financings totaling over $150 million and two Phase 2 clinical trials.</p> <p>His public company experience includes roles as Chairman and Chief Business Officer of BIOS Acquisition Corporation (NASDAQ: BIOS) and board member of Xeris Pharma (NASDAQ: XERS). As Chief Executive Officer of SteadyMed Therapeutics (NASDAQ: STDY), Rigby developed Trevyent for pulmonary arterial hypertension http://www.streetinsider.com/Board+Changes/ReAlta+Life+Sciences+appoints+Jonathan+Rigby+to+board+of+directors/25817311.html Wed, 07 Jan 2026 08:02:08 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR XERS ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html <p class="bwalignc"> <i>Bringing Decades of Successful Biotech Company Growth, Financing, IPO and M&amp;A Expertise</i> </p> <p> NORFOLK, Va.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Frealtalifesciences.com%2F&amp;esheet=54390380&amp;newsitemid=20260107978469&amp;lan=en-US&amp;anchor=ReAlta+Life+Sciences+Inc.&amp;index=1&amp;md5=50caf4621a489a2539ba28bbf67d1598" shape="rect">ReAlta Life Sciences Inc.</a> (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Jonathan Rigby as a member of the ReAlta Life Sciences Board of Directors. </p><p> Howard Berman, Ph.D., executive chairman, stated: “Jonathan brings a rare combination of entrepreneurial drive, disciplined company-building, and proven capital-markets execution. He has repeatedly demonstrated the ability to raise significant capital, http://www.streetinsider.com/Press+Releases/ReAlta+Life+Sciences+Announces+Appointment+of+Jonathan+Rigby+to+Board+of+Directors/25817204.html Wed, 07 Jan 2026 08:00:00 -0500 A.06872672 A.07889771 A.09265535 A.11478677 A.50100239 A.50201563 BIOS O.00186831 O.00258651 O.03791136 O.05831704 O.12272630 O.16558933 O.34955557 STDY UTHR ZGNX